PMC:7417114 / 54017-54549 11 Projects
Annnotations
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T444 | 0-21 | Sentence | denotes | Vandetanib (Caprelsa) |
| T445 | 22-83 | Sentence | denotes | (Sanofi Genzyme) Slow absorption; Cmax reached at median 6 h; |
| T446 | 84-197 | Sentence | denotes | Vd= 7450 L Metabolized by CYP3A4, flavin–containing monooxygenase enzymes FMO1 and FMO3 300 mg orally once daily; |
| T447 | 198-526 | Sentence | denotes | 90% binding (HSA) Interstitial lung disease and pneumonitis have been reported more often in patients receiving vandetanib as compared to those receiving placebo; fatal adverse reactions for patients receiving vandetanib (2%) were respiratory failure and arrest, aspiration pneumonia, cardiac failure with arrhythmia, and sepsis |
| T448 | 527-532 | Sentence | denotes | (231) |